Cerus Corp
NASDAQ:CERS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.52
2.42
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cerus Corp
Cerus Corp
Revenue
Cerus Corp
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cerus Corp
NASDAQ:CERS
|
Revenue
$197.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
18%
|
CAGR 10-Years
19%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Revenue
$1.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Revenue
$2.3B
|
CAGR 3-Years
22%
|
CAGR 5-Years
13%
|
CAGR 10-Years
23%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Revenue
$4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
18%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Revenue
$1.5B
|
CAGR 3-Years
57%
|
CAGR 5-Years
34%
|
CAGR 10-Years
18%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Revenue
$1.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
Cerus Corp
Glance View
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.
See Also
What is Cerus Corp's Revenue?
Revenue
197.9m
USD
Based on the financial report for Sep 30, 2024, Cerus Corp's Revenue amounts to 197.9m USD.
What is Cerus Corp's Revenue growth rate?
Revenue CAGR 10Y
19%
Over the last year, the Revenue growth was 7%. The average annual Revenue growth rates for Cerus Corp have been 11% over the past three years , 18% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet
